Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI ® (maralixibat) oral solution and tablet formulation for the ...

Under the theme of Early Detection Drives Direction, Global Liver Institute’s annual #RareAware campaign challenges health systems, policymakers, and communities to recognize rare liver diseases ...

Cirrhosis can cause scar tissue to gradually replace healthy liver cells. In time, this can affect liver function and lead to hair, skin, and nail symptoms such as rashes and discoloration. Cirrhosis ...

Peking University, October 30, 2024: Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by ...

A small amount of fat in your liver is healthy, but when fat makes up more than 5% of your liver's weight, it can cause problems. At this point, doctors call it steatotic liver disease, although you ...

Liver disease includes any condition that damages your liver. Over time, scar tissue can build up in your liver. Scarring or fibrosis can progress over many years until you develop cirrhosis—the most ...

Fatty liver disease is rising quickly in India and doctors now describe it as a silent danger. In early stages, the liver ...

Approximately a quarter of individuals with primary sclerosing cholangitis experience moderate-severe pruritus.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for ...